Sillajen stock surges upon clinical trial announcement for Pexa-Vec

The share price of Sillajen, a biopharmaceutical company, has been surging after the company’s French partner announced their successful global clinical trials of anticancer treatment candidate Pexa-Vec for the first time.

he company’ stocked surged to a record of 45,600 won ($40) on the Korea Stock Exchange Monday, up 23.9 percent, from the previous trading day.

Global phase 1b trial results announced at the European Oncology Society in Madrid confirmed the safety of the combination chemotherapy of Pexa-Vec and Cyclophosphamide.

Read the full story at Korea Biomedical Review